Brief: Repare Therapeutics Presents RP-3500 Dose Selection Phase 1 Monotherapy Safety Data From The Phase 1/2 TRESR Clinical Trial At The 2022 ESMO Targeted Anticancer Therapies Congress
07/03/2022 12:39
March 7 (Reuters) - Repare Therapeutics Inc RPTX.O :
* REPARE THERAPEUTICS PRESENTS RP-3500 DOSE SELECTION PHASE
1
MONOTHERAPY SAFETY DATA FROM THE PHASE 1/2 TRESR CLINICAL TRIAL
AT THE 2022 ESMO TARGETED ANTICANCER THERAPIES CONGRESS
* REPARE THERAPEUTICS INC - DOSE OPTIMIZATION PROVIDES
ROBUST
EVIDENCE TO ADVANCE RP-3500 INTO PHASE 2 STUDIES WITH A
RECOMMENDED DOSE AND SCHEDULE
Source text for Eikon: ID:nBw1zrwhya
Further company coverage: RPTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Repare Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Repare Therapeutics Announces Acquisition Of Polθ ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration
Brief: Repare Signs Support Agreements With Key Shareholders For Xenotherapeutics Deal
Repare Therapeutics Q2 net loss narrows to $16.7 mln